Lopinavir/Ritonavir (LPV/r) Tablet in HIV Infected Children

Status Completed

Clinical Trial Summary

To study the pharmacokinetics of low-dose lopinavir/ritonavir tablet in HIV-1 infected Thai children.

Clinical Trial Description

This is an open-label, single arm study to compare standard dose with a new tablet formulation of a lower dose of lopinavir/ritonavir in HIV-1 infected children. ;

Study Design

Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label

Related Conditions & MeSH terms

HIV-1 Infections

Clinical Trial Details

NCT number	NCT01139905
Study type	Interventional
Source	The HIV Netherlands Australia Thailand Research Collaboration
Contact
Status	Completed
Phase	Phase 2
Start date	April 2010
Completion date	March 2011

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01013415` - CD4-ZETA Gene Modified T Cells With and Without Exogenous Interleukin-2 (IL-2) In HIV Patients	Phase 1
Active, not recruiting	`NCT02923713` - TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV	Phase 2
Completed	`NCT01151319` - Safety and Immunogenicity Study of Three Candidate HIV-1 Vaccines, Administered in Combination to Healthy HIV-1 Uninfected Adults	Phase 1
Completed	`NCT01138605` - TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV	Phase 2
Completed	`NCT01078233` - Observational Data Analysis in EuroSIDA (MK-0518-058)
Recruiting	`NCT02593409` - HIV PrEP Priming of Immune Effectors	Phase 4
Completed	`NCT00557245` - Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples	Phase 3
Withdrawn	`NCT00984152` - Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women	Phase 3
Completed	`NCT00799058` - A Safety Study of Two Dapivirine (TMC120) Vaginal Gels in the United States	Phase 1/Phase 2
Completed	`NCT01159275` - Lopinavir (LPV) Dose Reduction	Phase 1/Phase 2
Completed	`NCT01281813` - TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV	Phase 3
Completed	`NCT01078246` - Post-Licensure Safety Study of ISENTRESS™ (Raltegravir) in a United States Managed Care Network (MK-0518-268)
Active, not recruiting	`NCT03027297` - TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV	Phase 3
Completed	`NCT01033760` - Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)	Phase 3
Completed	`NCT00830804` - Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults	Phase 2
Completed	`NCT01074931` - Clinical, Virological and Safety Outcomes of a Lopinavir/Ritonavir-Based Regimen in HIV-1 Infected Patients in Routine Clinical Use in China	N/A